AR061647A1 - Inhibidores de cxcr2 y sus composiciones farmaceuticas - Google Patents

Inhibidores de cxcr2 y sus composiciones farmaceuticas

Info

Publication number
AR061647A1
AR061647A1 ARP070102826A ARP070102826A AR061647A1 AR 061647 A1 AR061647 A1 AR 061647A1 AR P070102826 A ARP070102826 A AR P070102826A AR P070102826 A ARP070102826 A AR P070102826A AR 061647 A1 AR061647 A1 AR 061647A1
Authority
AR
Argentina
Prior art keywords
atoms
substituted
hydrogen
alkyl
fluorine
Prior art date
Application number
ARP070102826A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR061647A1 publication Critical patent/AR061647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Debido a sus propiedades como inhibidores de receptores de quimioquinas, especialmente como inhibidores de CXCR2, los compuestos de la formula 1 y las sales farmacéuticamente aceptables y profármacos de los mismos son adecuados para la prevencion y tratamiento de enfermedades mediadas por quimioquinas. Reivindicacion 1: Un compuesto de la formula (1) en la que X es -CR3=CR4-, -CR5=N-, -N=CR6-, -NR7- o -S-; R3, R4, R5 y R6 son, independientemente entre sí, hidrogeno, F, CI, Br, I, alquilo C1- 6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, alcoxi C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalcoxi C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalcoxi C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, -S-alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, OH, CN, NO2, NR27R28, C(O)R29, C(O)NR30R31, S(O)oR32, S(O)pNR33R34, arilo, heteroarilo, arilalquilo con alquilo C1-4 o heteroarilalquilo C1-4; R27 es hidrogeno o alquilo C1-4; R28 es hidrogeno, alquilo C1-4, arilo, C(O)H, C(O)alquilo C1-4 o C(O)arilo; R29 es hidrogeno, OH, alquilo C1-4, alcoxi C1-4 o arilo; R30, R31, R33 y R34 son, independientemente entre sí, hidrogeno, alquilo C1-4 o arilo; R32 es OH, alquilo C1-4, alcoxi C1-4 o arilo; o y p son, independientemente entre sí, 1 o 2; R7 es hidrogeno, alquilo C1-4 o C(O)R35; R35 es hidrogeno, alquilo C1-4 o arilo; Y1, Y2, Y3 e Y4 son, independientemente entre sí, -CR8- o nitrogeno, con la condicion de que al menos dos de Y1, Y2, Y3 e Y4 se definan como -CR8-; R8 es hidrogeno, F, CI, Br, I, alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, alcoxi C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalcoxi C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalcoxi C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, -S-alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, OH, CN, NO2, NR36R37, C(O)R38, C(O)NR39R40, S(O)qR41, S(O)rNR42R43, arilo, heteroarilo, arilalquilo con alquilo C1-4 o heteroarilalquilo con alquilo C1-4; R36 es hidrogeno o alquilo C1-4; R37 es hidrogeno, alquilo C1-4, arilo, C(O)H, C(O)alquilo C1-4 o C(O)arilo; R38 es hidrogeno, OH, alquilo C1-4, alcoxi C1-4 o arilo; R39, R40, R42 y R43 son, independientemente entre sí, hidrogeno, alquilo C1-4 o arilo; R41 es OH, alquilo C1-4, alcoxi C1-4 o arilo; q y r son, independientemente entre sí, 1 o 2; Z es -C(O)-, -S(O)- o -S(O)2-; A es cicloalquilo C3-8, heterociclilo que tiene 5, 6, 7 u 8 átomos, fenilo o heteroarilo que tiene 5 o 6 átomos; donde dicho cicloalquilo, heterociclilo, fenilo o heteroarilo puede estar condensado con un radical cicloalquilo C3-8, un radical heterociclilo que tiene 5, 6, 7 u 8 átomos, un radical fenilo o un radical heteroarilo que tiene 5 o 6 átomos, y donde dicho cicloalquilo, heterociclilo, fenilo o heteroarilo y el radical cicloalquilo, radical heterociclilo, radical fenilo o radical heteroarilo opcionalmente condensados está sin sustituir o sustituido con 1, 2, 3, 4 o 5 radicales seleccionados entre el grupo que consiste en F, CI, Br, I, OH, CN, NO2, SF5, alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, alcoxi C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalcoxi C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalcoxi C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor o -S-alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor; B es un enlazador lineal que consiste en 3, 4 o 5 átomos de carbono, donde 1 o 2 átomos de carbono pueden estar reemplazados por un miembro de un grupo que contiene heteroátomos que consiste en O, NR19 o S(O)y y dicho enlazador puede contener 0, 1 o 2 dobles o triples enlaces entre átomos de carbono dentro del enlazador, con las condiciones de que 2 de dichos grupos que contienen heteroátomos se separen al menos con 2 átomos de carbono, de que los grupos que contienen heteroátomos no sean adyacentes a un doble o triple enlace dentro del enlazador o a un doble enlace no aromático que puede ser parte de A, de que los dobles o triples enlaces no estén acumulados, y de que, si A está conectado al enlazador mediante un átomo de nitrogeno que forma parte de A, el átomo del enlazador que está conectado a A sea un átomo de carbono; y donde los átomos de carbono saturados del enlazador, que no son adyacentes a los grupos que contienen heteroátomos, que no son adyacentes a dobles o triples enlaces dentro del enlazador o que no son adyacentes a un heteroátomo, que puede ser parte de A, pueden estar sustituidos, independientemente entre sí, con hidrogeno, F, OH, alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, alcoxi C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor; cicloalcoxi C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor o cicloalquilalcoxi C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor; y donde los átomos de carbono saturados del enlazador, que son adyacentes a los grupos que contienen heteroátomos, que son adyacentes a los dobles o triples enlaces del enlazador, o que son adyacentes a un heteroátomo, que puede ser parte de A, o átomos de carbono que forman parte de un doble enlace, pueden estar sustituidos, independientemente entre sí, con hidrogeno, F, alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor o cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno pueden estar sustituidos con átomos de fluor; R19 es hidrogeno, alquilo C1-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilo C3-6, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 átomos de hidrogeno pueden estar sustituidos con átomos de fluor, cicloalquilalquilo C4-8, donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 o 15 átomos de hidrogeno estar sustituidos con átomos de fluor; C(O)R44 o C(O)NR45R46; R44, R45 y R46 son, independientemente entre sí, hidrogeno, alquilo C1-4, donde 1, 2, 3, 4, 5, 6 o 7 átomos de hidrogeno pueden estar sustituidos con átomos de fluor o cicloalquilo C3-4, donde 1, 2, 3, 4, 5 o 6 átomos de hidrogeno pueden estar sustituidos con átomos de fluor; y es 0, 1 o 2; R1 es alquilo C1-6; que puede estar sin sustituir o sustituido con 1, 2, 3, 4 o 5 radicales seleccionados entre el grupo que consiste en F, CI, Br, I y -Om-(CH2)n- R26; m es 0 o 1; n es 0, 1, 2 o 3; R26 es hidrogeno, fenilo, heteroarilo que tiene 5 o 6 átomos, cicloalquilo C3-6 o heterociclilo que tiene 3, 4, 5, 6, 7 u 8 átomos, donde el fenilo, heteroarilo, cicloalquilo o heterociclilo está sin sustituir o sustituido con 1, 2 o 3 radicales seleccionados entre F, CI, Br o I; y R2 es alquilo C1-6, fenilo, heteroarilo que tiene 5 o 6 átomos, cicloalquilo C3-8 o heterociclilo que tiene 3, 4, 5, 6, 7 u 8 átomos; donde el alquilo está sin sustituir o sustituido con 1, 2, 3, 4 o 5 radicales seleccionados entre el grupo que consiste en F, CI, Br, I y -Om-(CH2)n-R26; m es 0 o 1; n es 0, 1, 2 o 3; R26 es hidrogeno, fenilo, heteroarilo que tiene 5 o 6 átomos, cicloalquilo C3-6 o heterociclilo que tiene 3, 4, 5, 6, 7 u 8 átomos, donde el fenilo, heteroarilo, cicloalquilo o heterociclilo está sin sustituir o sustituido con 1, 2 o 3 radicales seleccionados entre F, CI, Br o I; y donde el fenilo, heteroarilo que tiene 5 o 6 átomos, cicloalquilo C3-8 o heterociclilo que tiene 3, 4, 5, 6, 7 u 8 átomos está sin sustituir o sustituido con 1, 2, 3, 4 o 5 radicales seleccionad
ARP070102826A 2006-06-28 2007-06-26 Inhibidores de cxcr2 y sus composiciones farmaceuticas AR061647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013323 2006-06-28

Publications (1)

Publication Number Publication Date
AR061647A1 true AR061647A1 (es) 2008-09-10

Family

ID=37086097

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102826A AR061647A1 (es) 2006-06-28 2007-06-26 Inhibidores de cxcr2 y sus composiciones farmaceuticas

Country Status (16)

Country Link
US (1) US8501981B2 (es)
EP (1) EP2040688B1 (es)
JP (1) JP5237938B2 (es)
KR (1) KR20090023645A (es)
CN (1) CN101478962A (es)
AR (1) AR061647A1 (es)
AU (1) AU2007264114A1 (es)
BR (1) BRPI0713064A2 (es)
CA (1) CA2656150A1 (es)
CL (1) CL2007001901A1 (es)
IL (1) IL196067A0 (es)
MX (1) MX2008015768A (es)
MY (1) MY145328A (es)
NO (1) NO20090075L (es)
TW (1) TW200817311A (es)
WO (1) WO2008000409A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CN102558021A (zh) 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
MX2009011615A (es) * 2007-06-05 2009-11-10 Sanofi Aventis Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
CN105418450A (zh) 2008-05-05 2016-03-23 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
BR112012000353B1 (pt) 2009-07-06 2020-06-02 Astrazeneca Ab Composto de fórmula markush, uso do composto, processos de reação com agente de acetilação e processo para preparação de um composto
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
WO2012079154A1 (en) * 2010-12-14 2012-06-21 Dalhousie University Selective estrogen receptor modulators
CR20160557A (es) * 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
CN115368230B (zh) * 2021-05-18 2023-09-08 心远(广州)药物研究有限公司 一种rxr激动剂的制备方法
TW202337453A (zh) 2022-03-17 2023-10-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962224A (en) 1987-12-23 1990-10-09 American Home Products Corporation N-naphthoylglycines as aldose reductase inhibitors
US4994477A (en) 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
CN102977016B (zh) 2003-06-06 2015-01-14 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7582775B2 (en) 2003-11-20 2009-09-01 Eli Lilly And Company Vitamin D receptor modulators
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006040646A1 (en) 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
CN101098852A (zh) 2004-11-09 2008-01-02 史密丝克莱恩比彻姆公司 糖原磷酸化酶抑制剂化合物和其药物组合物
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
AR055319A1 (es) 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos

Also Published As

Publication number Publication date
CL2007001901A1 (es) 2008-01-18
US8501981B2 (en) 2013-08-06
CN101478962A (zh) 2009-07-08
JP2009541382A (ja) 2009-11-26
NO20090075L (no) 2009-03-02
EP2040688A1 (en) 2009-04-01
CA2656150A1 (en) 2008-01-03
BRPI0713064A2 (pt) 2012-07-17
KR20090023645A (ko) 2009-03-05
TW200817311A (en) 2008-04-16
JP5237938B2 (ja) 2013-07-17
WO2008000409A1 (en) 2008-01-03
MY145328A (en) 2012-01-31
IL196067A0 (en) 2009-09-01
US20090227625A1 (en) 2009-09-10
EP2040688B1 (en) 2014-04-02
AU2007264114A1 (en) 2008-01-03
MX2008015768A (es) 2009-01-07

Similar Documents

Publication Publication Date Title
AR061647A1 (es) Inhibidores de cxcr2 y sus composiciones farmaceuticas
AR083167A1 (es) Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR082619A1 (es) Inhibidores del virus de la hepatitis c
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR076460A1 (es) Antagonistas del receptor cxcr3
AR070437A1 (es) Moduladores de beta - amiloide
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
AR074306A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR042024A1 (es) Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR072281A1 (es) Isoquinolinas e isoquinolinonas sustituidas
AR068466A1 (es) Cianoisoquinolina
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR059886A1 (es) Derivados de amidas como inhibidores de renina
PE20190980A1 (es) Compuestos terapeuticos y metodos para utilizarlos

Legal Events

Date Code Title Description
FB Suspension of granting procedure